Roche (SIX: RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing
forces for Roche Applied Science´s RealTime ready assays and Exiqon`s miRCURY
LNA? Universal RT microRNA qPCR system. As indicated by respective links on
their websites, each system will complement the cooperator ´s product
portfolio. A bundle of measures like webinars and seminars and linked internet
appearances are planned to promote the joined offer. Financial terms of the
agreement were not disclosed.

Roche Applied Science´s RealTime ready assays offer maximized testing
efficiency. Tar-gets of choice are selectable out of gene lists of
functionally related gene families or biological pathways. They can be ordered
as single assays or configured as custom panel on a LightCycler® 480 Multiwell
Plate. The function tested qPCR assays based on the proven Universal
ProbeLibrary technology enable for optimum results, with detailed
bioinformatics background information and novel error-detection features. The
RealTime ready assays allow for discovery of the functionality of targets in
complex biological pathways, to research their influence on processes leading
to diseases or disorders.

Exiqon's miRCURY LNA? Universal RT microRNA PCR system offers a combination of
performance and ease-of-use on the microRNA real-time PCR market. The use of
LNA?-enhanced PCR primers secures exceptional sensitivity and specificity
enabling accurate quantification of very low amounts of microRNA obtained from
difficult samples such as FFPE, serum/plasma and laser capture microscopy. The
product line which includes re-agents for the LightCycler® 480 System consists
of microRNA Ready-to-Use PCR panels for expression profiling of human and
rodent microRNAs, individual microRNA assays, reference genes and reagent kits.

Please see the full press release in the attached PDF.

pr_rocheexiqonpcr_jointmarketing_english.pdf